Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: A meta-analysis

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 561-569

  Zhang, Shoude ^a   Chen, Jia ^a   Jiang, Hua ^a   Ma, Haina ^a   Yang, Beibei ^a  

^a Second Affiliated Hospital   (China)

Author keywords

Advanced HNSCC; Anti EGFR therapy; Meta analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; ZALUTUMUMAB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; META ANALYSIS; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG ERUPTIONS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84864289875     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1194-1     Document Type: Article

References (45)

1. Choong N, Vokes E (2008) Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58(1):32-53
2. American Cancer Society (2011) Cancer facts and figures 2011. ACS, Atlanta
3. Lee J, Moon C (2011) Current status of experimental therapeutics for head and neck cancer. Exp Biol Med 236(4):375-389
4. Papaspyrou G, Werner JA et al (2011) Pharmacotherapy for squamous-cell carcinoma of the head and neck. Expert Opin Pharmacother 12(3):397-409
5. Seiwert TY, Salama JK et al (2007) The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4(3):156-171 (Pubitemid 46358853)
6. Goerner M, Seiwert TY et al (2010) Molecular targeted therapies in head and neck cancer - an updated of recent developments. Head Neck Oncol 2:8
7. Hynes NE, Lane HA (2005) Erbb receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341-354 (Pubitemid 40637826)
8. Szabó B, Nelhubel GA et al (2011) Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47(6):487-496
9. Ang KK, Berkey BA et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (24):7350-7356 (Pubitemid 36025259)
10. Grandis R, Melhem MF et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824-832 (Pubitemid 28280548)
11. Gold KA, Lee HYet al (2009) Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115(5):922-35
12. Bonner JA, Harari PM (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (6):567-78 (Pubitemid 43209104)
13. Ramakrishnan MS, Eswaraiah A et al (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Mabs 1(1):41-48
14. Chou J, Lin YC et al (2008) Nasopharyngeal carcinoma - review of the molecular mechanisms of tumorigenesis. Head Neck 30 (7):946-963 (Pubitemid 352008957)
15. Chan AT, Felip E et al. (2009) Nasopharyngeal cancer: EMSO clinical recommendations for diagnosis treatment and follow-up. Ann Oncol Suppl 4:123-125
16. Siersema PD (2008) Esophageal cancer. Gastroenterol Clin North Am 37(4):943-964
17. Williamson PR, Smith CT et al (2002) Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21(22):3337-3351 (Pubitemid 35314654)
18. Jadad AR, Moore RA et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12 (Pubitemid 26120810)
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558 (Pubitemid 34746062)
20. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
21. Egger M, Davey Smith G (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
22. Del Campo JM, Sebastian P (2008) Results: of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck. Abstract #688O. 3rd ESMO Congress
23. Rodríguez MO, Rivero TC et al (2010) Nimotuzumab plus radiotherapy for unresectable squamous cell carcinoma of the head and neck. Cancer Biol Ther 9(5):343-349
24. Harrington KJ, Berrier A et al. (2010) Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy in patients with locally advanced, unresected squamous cell carcinoma of the head and neck. Abstract #5505. ASCO
25. Burtness B, Goldwasser MA et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(34):8646-8654 (Pubitemid 46211507)
26. Vermorken JB, Mesia R et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (11):1116-1127
27. Stewart JS, Cohen EE et al (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27(11): 1864-1871
28. Argiris A, Ghebremichael M et al. (2009) A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: a trial of Eastern Cooperative Oncology Group. ASCO
29. Machiels JP, Subramanian S et al (2011) Zalutumumab plus best supportive care alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12(4):333-343
30. Pazdur R (2008) Endpoints for assessing drug activity in clinical trials. Oncologist Suppl 2:19-21
31. Feng FY, Lopez CA et al (2007) Effect of epidermal factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 13 (8):2512-2518 (Pubitemid 46698604)
32. Vivanco I, Mellinghoff IK (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 22(6):573-578
33. Cohen MH, Williams GA et al (2004) United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10(4):1212-1218 (Pubitemid 38365209)
34. Golsteyn RM (2005) Gefitinib dose not increase survival in lung cancer patients. Drug Discov Today 10(6):381 (Pubitemid 40450266)
35. Carlson JJ (2009) Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev Pharmacoecon Outcome Res 9(5):409-416
36. Rothenberg ML, LaFleur B et al (2005) Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23(36):9265-9274
37. Santoro A, Comandone A et al (2008) A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 19(11):1888-1893
38. Viéitez JM, Valladares M et al (2011) A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Invest New Drugs 29(5):1038-1044
39. da Cunha Santos G, Shepherd FA et al (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49-69
40. Oh BY, Lee RA et al (2011) Epidermal growth factor receptor mutations in colorectal cancer patients. J Korean Soc Coloproctol 27(3):127-132
41. Cooper JB, Cohen EE et al (2009) Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 31(8):1086-1094
42. Chen P, Wang L et al (2011) EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67(3):235-243
43. Dassonville O, Bozec A et al (2007) EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62(1):53-61 (Pubitemid 46330798)
44. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803-812 (Pubitemid 44450468)
45. Sipples R (2006) Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 1 (Suppl 1):28-34 (Pubitemid 43564198)